Skip to content
Medical Health Aged Care, Research Development

Training Hospital Staff in Person-Centred Dementia Care Improves Recovery Outcomes

Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney 2 mins read

New Australian study shows how tailored education for hospital staff is improving care for people with dementia.

A new study led by Prof. Lynn Chenoweth from UNSW’s Centre for Healthy Brain Ageing (CHeBA) has shown that educating hospital staff in person-centred dementia care leads to better care experiences, greater staff confidence, and improved rehabilitation outcomes for older Australians.

Published in Geriatric Nursing, the study evaluated a dementia care education program delivered to nurses, doctors and allied health professionals at a sub-acute aged care rehabilitation hospital. The goal was to help staff better support older patients with dementia as they recover from injury or illness.

The results were striking. Six months after completing the training, staff reported significantly greater confidence and understanding in how to care for people with dementia. Observations showed more meaningful communication and engagement with patients, and overall improvements in service quality.

“This kind of care recognises the whole person - not just their illness,” said Professor Chenoweth. “When staff are equipped to see and respond to the individual needs, abilities and preferences of people with dementia, outcomes improve - not just clinically, but emotionally and socially.”

The education was based on the Kitwood model of person-centred care, a globally recognised approach that prioritises dignity, respect and emotional wellbeing in dementia care. It also encouraged staff to involve family members and focus on the goals that matter most to the person receiving care.

Prof. Henry Brodaty, internationally respected dementia expert and co-author of the study, said: “Person-centred care is vital in healthcare. It helps people with dementia feel valued, understood and empowered, even in hospital settings that can otherwise be confusing or distressing. This study confirms the value of educating staff to adopt that mindset and approach.”

The program also led to lasting changes across the hospital, with updated policies, new communication tools, and more collaborative care planning between staff, patients and families.

The researchers say the findings offer a clear path for other hospitals and aged care settings to improve dementia care through education and culture change.

“Small changes in how we train and support our staff can make a big difference to how older people with dementia experience care and recovery,” Prof. Chenoweth said.

 

 

  • ENDS -

About us:

CHeBA is a self-funded research centre with a vision to achieve, through research, healthier brain ageing and better clinical care of age-related brain diseases. Centre for Healthy Brain Ageing (CHeBA) | UNSW Sydney


Contact details:

Helena Hudson, Centre for Healthy Brain Ageing - 0414 292 383

[email protected]

Media

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Medical Health Aged Care, Seniors Interest
  • 08/12/2025
  • 08:56
Monash University

Men and women may need different medications to avoid broken bones

A new international study, published in Osteoporosis International and led by Monash’s Centre for Medicine Use and Safety (CMUS), investigated the risks of a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.